Piccolo per l'età gestazionale

Ma che fine fanno gli SGA?

G. Tornese

2019/6 — pag. 355-364

Recombinant human growth hormone (rhGH) is an approved and effective treatment for short children born small for gestational age (SGA). Prevalence of children eligible for treatment as SGA is reported to be 1:1,800. The latest data from the Italian...

Gli errori commessi in un caso di diabete non autoimmune

R. Caiazzo, C. Coppola

2017/6

Il bambino nato piccolo per l’età gestazionale

R. Salomone, F. Chiarelli

2007/6 — pag. 363-369

Being small for gestational (SGA) leads to consequences not only in the neonatal period but also in adulthood. During the last 15 years, a number of long term risks of being SGA have been clearly identified, including hypertension, ischaemic heart ...

Il ritardo di crescita intrauterina: una condizione multifattoriale

R. Bortolus, F. Parazzini, D. Trevisanuto

1997/3 — pag. 159-163

This review describes the main risk factors for small for gestational age (SGA). Fifteen percent of infants born each year in the world are low birth weight (less than 2500 g), and 90% of these infants are born in developing countries. Most of L...